Application of Multicriteria Decision Analysis to Determine the Value of Prophylaxis Relative to On-Demand Treatment in Hemophilia A and Emicizumab versus Replacement Therapy in the Greek Healthcare Setting

被引：0

作者：

George Gourzoulidis

Garyfallia Stefanou

Marina Economou

Sofia Vakalopoulou

George Filippidis

George Soultatis

Dimitrios Kontos

Sotiria Tzima

Fotis Ntemousis

Angeliki Fassa

Georgia Kourlaba

机构：

[1] University of West Attica,Department of Public Health Policy, School of Public Health

[2] ECONCARE LP,1st Pediatric Department

[3] Aristotle University Thessaloniki,2nd Propedeutic Department of Internal Medicine

[4] Hippocratio Hospital,undefined

[5] Hippokration General Hospital of Thessaloniki,undefined

[6] Aristotle University of Thessaloniki,undefined

[7] Greek Haemophilia Society,undefined

[8] Laiko General Hospital,undefined

[9] Panhellenic Pharmaceutical Association,undefined

[10] Roche Hellas S.A,undefined

来源：

Clinical Drug Investigation | 2022年 / 42卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：75 / 85

页数：10

共 19 条

[11] Cost-effectiveness analysis of primary prophylaxis versus on-demand treatment for individuals with severe hemophilia based on the Joint Outcome Study
Matthew, P.
Boer, R.
Lalla, A.
Preblick, R.
Pocoski, J.
HAEMOPHILIA, 2010, 16 : 58 - 58
[12] Cost-effectiveness analysis of low-dose prophylaxis versus on-demand treatment for moderate-to-severe hemophilia A in India
Seth, Tulika
Garg, Kapil
Mandal, Prakas Kumar
Datta, Anupam
Verma, Shailendra
Hanagavadi, Suresh
Thota, Usha Rani
HEMATOLOGY, 2023, 28 (01)
[13] ESTIMATING UTILITY WEIGHTS IN HEMOPHILIA A PATIENTS WITH INHIBITORS USING THE EQ-5D-5L TOOL: A COMPARISON OF EMICIZUMAB PROPHYLAXIS VERSUS ON-DEMAND TREATMENT WITH BYPASSING AGENTS
Park, S.
Baik, D.
Lee, H.
Han, J. W.
Park, Y. S.
Kim, H. C.
Kang, H. Y.
VALUE IN HEALTH, 2019, 22 : S867 - S867
[14] A Comparison of the Incidence Rate for Joint Bleeding and FVIII Consumption between On-Demand versus Prophylaxis Factor VIII Replacement Therapy and the Direct Cost of Prophylaxis Treatment in Severe Haemophilia A Patients
Jamal, Munirah
Sathar, Jameela
Jamari, Jamaliah
Saffian, Shamin Mohd
MALAYSIAN JOURNAL OF MEDICAL SCIENCES, 2023, 30 (01): : 129 - 136
[15] Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran
Rasekh, Hamid Reza
Imani, Ali
Karimi, Mehran
Golestani, Mina
CLINICOECONOMICS AND OUTCOMES RESEARCH, 2011, 3 : 207 - 212
[16] COST-UTILITY ANALYSIS OF IMMUNE TOLERANCE INDUCTION (ITI) THERAPY VERSUS ON-DEMAND TREATMENT WITH RECOMBINANT FVII (RFVIIA) FOR HEMOPHILIA A WITH HIGH TITER INHIBITORS IN IRAN
Imani, A.
Rasekh, H.
Golestani, M.
VALUE IN HEALTH, 2012, 15 (07) : A680 - A680
[17] Dutasteride plus Tamsulosin fixed-dose combination first-line therapy versus Tamsulosin Monotherapy in the treatment of benign prostatic hyperplasia: a budget impact analysis in the Greek healthcare setting
Geitona, Maria
Karabela, Pinelopi
Katsoulis, Ioannis A.
Kousoulakou, Hara
Lyberopoulou, Eleni
Bitros, Eleftherios
Xaplanteris, Loukas
Papanicolaou, Sotiria
BMC UROLOGY, 2014, 14
[18] Dutasteride plus Tamsulosin fixed-dose combination first-line therapy versus Tamsulosin Monotherapy in the treatment of benign prostatic hyperplasia: a budget impact analysis in the Greek healthcare setting
Maria Geitona
Pinelopi Karabela
Ioannis A Katsoulis
Hara Kousoulakou
Eleni Lyberopoulou
Eleftherios Bitros
Loukas Xaplanteris
Sotiria Papanicolaou
BMC Urology, 14
[19] Re: Dutasteride plus Tamsulosin Fixed-Dose Combination First-Line Therapy versus Tamsulosin Monotherapy in the Treatment of Benign Prostatic Hyperplasia: A Budget Impact Analysis in the Greek Healthcare Setting Editorial Comment
Kashyap, M.
Belleville, S.
Mulsant, B. H.
Hilmer, S. Nl
Paquette, A.
Tu, L. M.
Tannenbaum, C.
JOURNAL OF UROLOGY, 2015, 194 (05): : 1354 - 1355

← 1 2 →